Feasibility of Reduced-Dose Posttransplant Cyclophosphamide and Cotransplantation of Peripheral Blood Stem Cells and Umbilical Cord-Derived Mesenchymal Stem Cells for SAA

Scientists evaluated the effectiveness and safety of reduced-dose cyclophosphamide, 20 mg/kg for 13 patients in matched sibling donor hematopoietic stem cell transplantation (HSCT) cohort and 25 mg/kg for 22 patients in haplo-HSCT cohort, on days +3, +4 combined with cotransplantation of peripheral blood stem cells and human umbilical cord-derived MSCs for severe aplastic anemia (SAA).